NCT02921685 (PIRAT) is a Phase 1 clinical trial of Monalizumab in Hematologic Malignancies, sponsored by Institut Paoli-Calmettes.

Who is sponsoring NCT02921685?

NCT02921685 is sponsored by Institut Paoli-Calmettes.

What drugs are being tested in NCT02921685?

Interventions in NCT02921685: Monalizumab.

What condition does NCT02921685 study?

NCT02921685 studies Hematologic Malignancies.

Is NCT02921685 still recruiting?

NCT02921685 is currently status unknown. Last updated 19 September 2018.

Last reviewed 2018-09-19 · How we verify

NCT02921685: PIRAT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation

Status unknown Phase 1 Last updated 19 September 2018

What this trial tests

Phase 1 trial testing Monalizumab in Hematologic Malignancies in 18 participants. Status unknown.

Timeline

28 November 2016

Primary endpoint
28 May 2019

28 April 2020

Quick facts

Lead sponsor	Institut Paoli-Calmettes
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	28 November 2016
Primary completion	28 May 2019
Estimated completion	28 April 2020
Sites	1 location across France

Drugs / interventions tested

Monalizumab — full drug profile →

Conditions studied

Hematologic Malignancies — all drugs for Hematologic Malignancies →

Sponsor

Institut Paoli-Calmettes — full company profile →

Who can join

Adults 18 to 70, any sex, with Hematologic Malignancies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will determine the Maximal Tolerated Dose if any and the recommended dose for phase 2 of monalizumab, a monoclonal antibody directed against the CD94/NKG2A receptor, after allogenic stem cell transplantation. All patients will receive one single intravenous administration of one of the four doses of monalizumab.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies.
Bald T, Krummel MF, Smyth MJ, Barry KC. · · 2020 · cited 388× · PMID 32690952 · DOI 10.1038/s41590-020-0728-z
NK Cell-Based Immune Checkpoint Inhibition.
Khan M, Arooj S, Wang H. · · 2020 · cited 296× · PMID 32117298 · DOI 10.3389/fimmu.2020.00167
Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets.
Luo XY, Wu KM, He XX. · · 2021 · cited 144× · PMID 34006331 · DOI 10.1186/s13046-021-01968-w
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy.
Cao Y, Wang X, Jin T, Tian Y, et al · · 2020 · cited 133× · PMID 33122640 · DOI 10.1038/s41392-020-00348-8
Elevated <i>HLA-A</i> expression impairs HIV control through inhibition of NKG2A-expressing cells.
Ramsuran V, Naranbhai V, Horowitz A, Qi Y, et al · · 2018 · cited 129× · PMID 29302013 · DOI 10.1126/science.aam8825
Targeting Natural Killer Cells for Tumor Immunotherapy.
Zhang C, Hu Y, Shi C. · · 2020 · cited 91× · PMID 32140153 · DOI 10.3389/fimmu.2020.00060
The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy.
Sun H, Sun C. · · 2019 · cited 88× · PMID 31681269 · DOI 10.3389/fimmu.2019.02354
Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
Zhang C, Liu Y. · · 2020 · cited 75× · PMID 32714324 · DOI 10.3389/fimmu.2020.01295

Verify or expand the search:

Other trials of Monalizumab

Trials testing the same drug.

NCT06769126 — Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM · Phase 2 · recruiting
NCT06503614 — A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
NCT05903092 — MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer · Phase 2 · suspended
NCT05061550 — Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer · Phase 2 · recruiting
NCT05221840 — A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Ch · Phase 3 · active not recruiting

Other recruiting trials for Hematologic Malignancies

Currently open trials in the same condition.

NCT04546945 — Aberrant Expression of CD56 in Patients With Hematologic Malignancies. · recruiting
NCT06926595 — Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention · Phase 2 · recruiting
NCT07186192 — Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy · Phase 3 · recruiting
NCT07195916 — A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies · Phase 1 · recruiting
NCT07162038 — Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA- · Phase 1 · recruiting

Other Institut Paoli-Calmettes trials

Trials by the same sponsor.

NCT07461142 — Reduction of Hematologic Toxicity in Locally Advanced Cervical Cancers · NA · not yet recruiting
NCT06557421 — De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients · Phase 2 · recruiting
NCT06046794 — Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients · NA · recruiting
NCT06055621 — Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE · Phase 2 · recruiting
NCT05986071 — I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02921685 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut Paoli-Calmettes
Last refreshed: 19 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02921685.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing